Replies

Ivermectin for COVID-19: real-time meta analysis of 61 studies

•Meta analysis using the most serious outcome reported shows 74% and 85% improvement for early treatment and prophylaxis (RR 0.26 [0.16-0.43] and 0.15 [0.09-0.25]), with similar results after exclusion based sensitivity analysis, restriction to peer-reviewed studies, and restriction to Randomized Controlled Trials.

•64% and 96% lower mortality is observed for early treatment and prophylaxis (RR 0.36 [0.15-0.85] and 0.04 [0.00-0.58]). Statistically significant improvements are seen for mortality, hospitalization, cases, and viral clearance. 28 studies show statistically significant improvements in isolation.

	Studies	Prophylaxis	Early treatment	Late treatment	Patients	Authors
All studies	61	85% [75‑91%]	74% [57‑84%]	46% [29‑59%]	22,425	578
With exclusions	52	87% [75‑93%]	76% [66‑83%]	54% [33‑68%]	18,048	524
Peer-reviewed	37	88% [70‑95%]	74% [58‑84%]	42% [19‑58%]	11,352	390
Randomized Controlled Trials	32	83% [39‑95%]	67% [54‑76%]	40% [11‑60%]	5,817	369
Mortality results	23	96% [42‑100%]	64% [15‑85%]	61% [38‑76%]	11,184	234
Percentage improvement with ivermectin treatment